Educational article
Semaglutide vs. tirzepatide for obesity: differences and evidence
Educational content. It does not replace an individual medical assessment and should not be used for self-medication.

How the medicines work
Semaglutide acts on the GLP‑1 receptor. Tirzepatide acts on both GIP and GLP‑1 receptors. These are different active ingredients, and the indication depends on the formulation. The mechanism is only one part of choosing treatment.
What the head-to-head trial found
SURMOUNT‑5 compared the injectable formulations in adults with obesity without diabetes. At 72 weeks, the group assigned to tirzepatide lost more weight on average than the semaglutide group at the doses studied. Digestive symptoms were among the most frequent adverse effects in both groups.
What the trial cannot answer
Group averages do not predict a personal response. The trial also does not directly establish which choice fits all people with diabetes, other formulations or different doses. Your clinician also considers medical history, other medicines, tolerability, cost and continued access.
Prepare for a treatment discussion
Bring your treatment history, why you stopped any previous medicines and what you hope to improve. Ask which options are indicated in your case, how response will be assessed and what to do if you have trouble tolerating treatment. Avoid combining or switching medicines on your own.
When to seek medical care
If symptoms persist, test results are abnormal, or you have questions about medication, arrange an individual assessment. Do not change treatment or doses without medical guidance.
Frequently asked questions
Which one is best for me?
The trial can inform your discussion. Your clinician still needs to assess your goals, medical history and available options.
Are they the same medicine with different names?
They are different active ingredients. Each product has its own formulation and indication.
References
- Prescription Medications to Treat Overweight & Obesity · NIDDK
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT‑5) · New England Journal of Medicine
Does this topic resonate with you?
Every case is different. Book a consultation to review your history, test results and goals with a personalized plan.



